{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:16:07Z","timestamp":1787728567118,"version":"build-2784847793"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Health Research Project","award":["TJWJ2024QN008"],"award-info":[{"award-number":["TJWJ2024QN008"]}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Municipal Natural Science Foundation","doi-asserted-by":"crossref","award":["23JCQNJC00870"],"award-info":[{"award-number":["23JCQNJC00870"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Municipal Natural Science Foundation","doi-asserted-by":"crossref","award":["24ZGSSSS00050"],"award-info":[{"award-number":["24ZGSSSS00050"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M742624"],"award-info":[{"award-number":["2023M742624"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key research and development projects of the Ministry of Science and Technology","award":["2024YFC2510500"],"award-info":[{"award-number":["2024YFC2510500"]}]},{"name":"National Natural Science Foundation Project","award":["82270142"],"award-info":[{"award-number":["82270142"]}]},{"name":"National Natural Science Foundation Project","award":["81900131"],"award-info":[{"award-number":["81900131"]}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Planning Project","doi-asserted-by":"crossref","award":["24ZXGZSY0009"],"award-info":[{"award-number":["24ZXGZSY0009"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Planning Project","doi-asserted-by":"crossref","award":["24ZXGQSY00020"],"award-info":[{"award-number":["24ZXGQSY00020"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin Municipal Health Commission Project","award":["TJWJ2023XK003"],"award-info":[{"award-number":["TJWJ2023XK003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06319-3","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T12:28:06Z","timestamp":1742128086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K\/PDK1\/SGK3 pathway in patients with multiple myeloma"],"prefix":"10.1186","volume":"23","author":[{"given":"Fengjuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-1562","authenticated-orcid":false,"given":"Zhaoyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-9224","authenticated-orcid":false,"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"key":"6319_CR1","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133:1534\u20139.","journal-title":"Blood"},{"key":"6319_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, et al. NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022;20:8\u201319.","journal-title":"J Natl Compr Canc Netw"},{"key":"6319_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086\u2013107.","journal-title":"Am J Hematol"},{"key":"6319_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcdb.2020.10.006","volume":"112","author":"M Diaz-delCastillo","year":"2021","unstructured":"Diaz-delCastillo M, Chantry AD, Lawson MA, Heegaard AM. Multiple myeloma-A painful disease of the bone marrow. Semin Cell Dev Biol. 2021;112:49\u201358.","journal-title":"Semin Cell Dev Biol"},{"key":"6319_CR5","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.3390\/ijms24054893","volume":"24","author":"O Lungu","year":"2023","unstructured":"Lungu O, Toscani D, Burroughs-Garcia J, Giuliani N. The metabolic features of osteoblasts: implications for multiple myeloma (MM) bone disease. Int J Mol Sci. 2023;24:4893.","journal-title":"Int J Mol Sci"},{"key":"6319_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12935-014-0132-6","volume":"14","author":"R Fu","year":"2014","unstructured":"Fu R, Liu H, Zhao S, Wang Y, Li L, Gao S, Ruan E, Wang G, Wang H, Song J, Shao Z. Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell Int. 2014;14:132.","journal-title":"Cancer Cell Int"},{"key":"6319_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00277-016-2863-z","volume":"96","author":"F Jiang","year":"2017","unstructured":"Jiang F, Liu H, Liu Z, Song J, Li L, Ding K, Ren Y, Peng F, Shao Z, Fu R. High serum levels of complements C3 and C4 as novel markers for myeloma bone disease. Ann Hematol. 2017;96:331\u20133.","journal-title":"Ann Hematol"},{"key":"6319_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.20892\/j.issn.2095-3941.2020.0430","volume":"18","author":"F Jiang","year":"2021","unstructured":"Jiang F, Liu H, Peng F, Liu Z, Ding K, Song J, Li L, Chen J, Shao Q, Yan S, et al. Complement C3a activates osteoclasts by regulating the PI3K\/PDK1\/SGK3 pathway in patients with multiple myeloma. Cancer Biol Med. 2021;18:721\u201333.","journal-title":"Cancer Biol Med"},{"key":"6319_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bone.2016.11.028","volume":"95","author":"MD Cantley","year":"2017","unstructured":"Cantley MD, Zannettino ACW, Bartold PM, Fairlie DP, Haynes DR. Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone. 2017;95:162\u201374.","journal-title":"Bone"},{"key":"6319_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/emm.2007.24","volume":"39","author":"T Yi","year":"2007","unstructured":"Yi T, Baek JH, Kim HJ, Choi MH, Seo SB, Ryoo HM, Kim GS, Woo KM. Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis. Exp Mol Med. 2007;39:213\u201321.","journal-title":"Exp Mol Med"},{"key":"6319_CR11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1152\/physrev.00004.2015","volume":"95","author":"EW Bradley","year":"2015","unstructured":"Bradley EW, Carpio LR, van Wijnen AJ, McGee-Lawrence ME, Westendorf JJ. Histone deacetylases in bone development and skeletal disorders. Physiol Rev. 2015;95:1359\u201381.","journal-title":"Physiol Rev"},{"key":"6319_CR12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/jbmr.1824","volume":"28","author":"JR Edwards","year":"2013","unstructured":"Edwards JR, Perrien DS, Fleming N, Nyman JS, Ono K, Connelly L, Moore MM, Lwin ST, Yull FE, Mundy GR, Elefteriou F. Silent information regulator (Sir)T1 inhibits NF-\u03baB signaling to maintain normal skeletal remodeling. J Bone Miner Res. 2013;28:960\u20139.","journal-title":"J Bone Miner Res"},{"key":"6319_CR13","doi-asserted-by":"publisher","first-page":"11492","DOI":"10.1074\/jbc.M110.198713","volume":"286","author":"M Shakibaei","year":"2011","unstructured":"Shakibaei M, Buhrmann C, Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem. 2011;286:11492\u2013505.","journal-title":"J Biol Chem"},{"key":"6319_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.exphem.2013.02.008","volume":"41","author":"SU Venkateshaiah","year":"2013","unstructured":"Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S. NAMPT\/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013;41:547-557.e542.","journal-title":"Exp Hematol"},{"key":"6319_CR15","doi-asserted-by":"publisher","first-page":"H1003","DOI":"10.1152\/ajpheart.00676.2015","volume":"310","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Tamaki K, Shirakawa K, Ito K, Yan X, Katsumata Y, Anzai A, Matsuhashi T, Endo J, Inaba T, et al. Cardiac Sirt1 mediates the cardioprotective effect of caloric restriction by suppressing local complement system activation after ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2016;310:H1003-1014.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"6319_CR16","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.2337\/db11-0616","volume":"60","author":"MP Gillum","year":"2011","unstructured":"Gillum MP, Kotas ME, Erion DM, Kursawe R, Chatterjee P, Nead KT, Muise ES, Hsiao JJ, Frederick DW, Yonemitsu S, et al. SirT1 regulates adipose tissue inflammation. Diabetes. 2011;60:3235\u201345.","journal-title":"Diabetes"},{"key":"6319_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.18632\/aging.100464","volume":"4","author":"G Bolasco","year":"2012","unstructured":"Bolasco G, Calogero R, Carrara M, Banchaabouchi MA, Bilbao D, Mazzoccoli G, Vinciguerra M. Cardioprotective mIGF-1\/SIRT1 signaling induces hypertension, leukocytosis and fear response in mice. Aging (Albany NY). 2012;4:402\u201316.","journal-title":"Aging (Albany NY)"},{"key":"6319_CR18","doi-asserted-by":"publisher","first-page":"e81341","DOI":"10.1371\/journal.pone.0081341","volume":"8","author":"C Ehrnthaller","year":"2013","unstructured":"Ehrnthaller C, Huber-Lang M, Nilsson P, Bindl R, Redeker S, Recknagel S, Rapp A, Mollnes T, Amling M, Gebhard F, Ignatius A. Complement C3 and C5 deficiency affects fracture healing. PLoS One. 2013;8:e81341.","journal-title":"PLoS One"},{"key":"6319_CR19","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1182\/blood-2010-01-263590","volume":"116","author":"Z Tu","year":"2010","unstructured":"Tu Z, Bu H, Dennis JE, Lin F. Efficient osteoclast differentiation requires local complement activation. Blood. 2010;116:4456\u201363.","journal-title":"Blood"},{"key":"6319_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/endo.133.1.8319587","volume":"133","author":"T Sato","year":"1993","unstructured":"Sato T, Abe E, Jin CH, Hong MH, Katagiri T, Kinoshita T, Amizuka N, Ozawa H, Suda T. The biological roles of the third component of complement in osteoclast formation. Endocrinology. 1993;133:397\u2013404.","journal-title":"Endocrinology"},{"key":"6319_CR21","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1002\/jcb.23186","volume":"112","author":"A Ignatius","year":"2011","unstructured":"Ignatius A, Schoengraf P, Kreja L, Liedert A, Recknagel S, Kandert S, Brenner RE, Schneider M, Lambris JD, Huber-Lang M. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1\u03b2. J Cell Biochem. 2011;112:2594\u2013605.","journal-title":"J Cell Biochem"},{"key":"6319_CR22","doi-asserted-by":"publisher","first-page":"14061","DOI":"10.1038\/s41598-017-14444-3","volume":"7","author":"A Kovtun","year":"2017","unstructured":"Kovtun A, Bergdolt S, H\u00e4gele Y, Matthes R, Lambris JD, Huber-Lang M, Ignatius A. Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair. Sci Rep. 2017;7:14061.","journal-title":"Sci Rep"},{"key":"6319_CR23","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-548.","journal-title":"Lancet Oncol"},{"key":"6319_CR24","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"6319_CR25","doi-asserted-by":"publisher","first-page":"11969","DOI":"10.1002\/jcp.27852","volume":"234","author":"C Song","year":"2019","unstructured":"Song C, Yang X, Lei Y, Zhang Z, Smith W, Yan J, Kong L. Evaluation of efficacy on RANKL induced osteoclast from RAW264.7 cells. J Cell Physiol. 2019;234:11969\u201375.","journal-title":"J Cell Physiol"},{"key":"6319_CR26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00277-016-2657-3","volume":"95","author":"R Fu","year":"2016","unstructured":"Fu R, Peng F, Liu H, Wang Y, Li L, Wang G, Song J, Shao Z. Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease. Ann Hematol. 2016;95:1099\u2013106.","journal-title":"Ann Hematol"},{"key":"6319_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1177\/0022034513500306","volume":"92","author":"BF Boyce","year":"2013","unstructured":"Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 2013;92:860\u20137.","journal-title":"J Dent Res"},{"key":"6319_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/JOE-11-0212","volume":"211","author":"DJ Mellis","year":"2011","unstructured":"Mellis DJ, Itzstein C, Helfrich MH, Crockett JC. The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. J Endocrinol. 2011;211:131\u201343.","journal-title":"J Endocrinol"},{"key":"6319_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3892\/ijo.2016.3815","volume":"50","author":"H Liu","year":"2017","unstructured":"Liu H, Peng F, Liu Z, Jiang F, Li L, Gao S, Wang G, Song J, Ruan E, Shao Z, Fu R. CYR61\/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease. Int J Oncol. 2017;50:631\u20139.","journal-title":"Int J Oncol"},{"key":"6319_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159527","author":"D Gai","year":"2022","unstructured":"Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, et al. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI159527.","journal-title":"J Clin Invest"},{"key":"6319_CR31","doi-asserted-by":"publisher","first-page":"1017411","DOI":"10.3389\/fmed.2022.1017411","volume":"9","author":"D Wang","year":"2022","unstructured":"Wang D, Wang J, Zheng X, Diao S, Li W, Ma W. Bone homeostasis disorders increased the mortality of sepsis patients: a preliminary retrospective cohort study. Front Med (Lausanne). 2022;9:1017411.","journal-title":"Front Med (Lausanne)"},{"key":"6319_CR32","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.clinbiochem.2012.03.035","volume":"45","author":"SA Chubb","year":"2012","unstructured":"Chubb SA. Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin Biochem. 2012;45:928\u201335.","journal-title":"Clin Biochem"},{"key":"6319_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ijc.11247","volume":"106","author":"E Terpos","year":"2003","unstructured":"Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM, Rahemtulla A. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer. 2003;106:455\u20137.","journal-title":"Int J Cancer"},{"key":"6319_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/clinchem\/47.4.686","volume":"47","author":"HW Woitge","year":"2001","unstructured":"Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem. 2001;47:686\u201393.","journal-title":"Clin Chem"},{"key":"6319_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1600-0609.2010.01417.x","volume":"84","author":"T Lund","year":"2010","unstructured":"Lund T, Abildgaard N, Andersen TL, Delaisse JM, Plesner T. Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol. 2010;84:412\u201320.","journal-title":"Eur J Haematol"},{"key":"6319_CR36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.clinbiochem.2009.12.018","volume":"43","author":"M Kowalska","year":"2010","unstructured":"Kowalska M, Druzd-Sitek A, Fuksiewicz M, Kotowicz B, Chechlinska M, Syczewska M, Walewski J, Kaminska J. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma. Clin Biochem. 2010;43:604\u20138.","journal-title":"Clin Biochem"},{"key":"6319_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s00198-011-1666-2","volume":"23","author":"P D'Amelio","year":"2012","unstructured":"D\u2019Amelio P, Tamone C, Sassi F, D\u2019Amico L, Roato I, Patan\u00e8 S, Ravazzoli M, Veneziano L, Ferracini R, Pescarmona GP, Isaia GC. Teriparatide increases the maturation of circulating osteoblast precursors. Osteoporos Int. 2012;23:1245\u201353.","journal-title":"Osteoporos Int"},{"key":"6319_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.biopha.2018.05.030","volume":"104","author":"L Zhang","year":"2018","unstructured":"Zhang L, Bao D, Li P, Lu Z, Pang L, Chen Z, Guo H, Gao Z, Jin Q. Particle-induced SIRT1 downregulation promotes osteoclastogenesis and osteolysis through ER stress regulation. Biomed Pharmacother. 2018;104:300\u20136.","journal-title":"Biomed Pharmacother"},{"key":"6319_CR39","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.3390\/ijms23094776","volume":"23","author":"MF McCarty","year":"2022","unstructured":"McCarty MF, Lewis Lujan L, Assanga SI. Targeting Sirt1, AMPK, Nrf2, CK2, and soluble guanylate cyclase with nutraceuticals: a practical strategy for preserving bone mass. Int J Mol Sci. 2022;23:4776.","journal-title":"Int J Mol Sci"},{"key":"6319_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/bs.ctdb.2017.10.004","volume":"127","author":"HN Kim","year":"2018","unstructured":"Kim HN, Iyer S, Ring R, Almeida M. The role of FoxOs in bone health and disease. Curr Top Dev Biol. 2018;127:149\u201363.","journal-title":"Curr Top Dev Biol"},{"key":"6319_CR41","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41422-019-0175-2","volume":"29","author":"F Zhong","year":"2019","unstructured":"Zhong F, Hu Z, Jiang K, Lei B, Wu Z, Yuan G, Luo H, Dong C, Tang B, Zheng C, et al. Complement C3 activation regulates the production of tRNA-derived fragments Gly-tRFs and promotes alcohol-induced liver injury and steatosis. Cell Res. 2019;29:548\u201361.","journal-title":"Cell Res"},{"key":"6319_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nature06261","volume":"450","author":"JC Milne","year":"2007","unstructured":"Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450:712\u20136.","journal-title":"Nature"},{"key":"6319_CR43","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/JPER.21-0657","volume":"93","author":"Q Ye","year":"2022","unstructured":"Ye Q, Xu H, Liu S, Li Z, Zhou J, Ding F, Zhang X, Wang Y, Jin Y, Wang Q. Apoptotic extracellular vesicles alleviate Pg-LPS induced inflammatory responses of macrophages via AMPK\/SIRT1\/NF-\u03baB pathway and inhibit osteoclast formation. J Periodontol. 2022;93:1738\u201351.","journal-title":"J Periodontol"},{"key":"6319_CR44","first-page":"1000235","volume":"11","author":"R Thiyagarajan","year":"2023","unstructured":"Thiyagarajan R, Gonzalez MR, Zaw C, Seldeen KL, Hernandez M, Pang M, Troen BR. SRT2183 and SRT1720, but not resveratrol, inhibit osteoclast formation and resorption in the presence or absence of Sirt1. J Bone Res. 2023;11:1000235.","journal-title":"J Bone Res"},{"key":"6319_CR45","doi-asserted-by":"publisher","first-page":"110827","DOI":"10.1016\/j.cbi.2023.110827","volume":"388","author":"Z Tao","year":"2024","unstructured":"Tao Z, Tao M, Zhou M, Wu XJ. Niacin treatment prevents bone loss in iron overload osteoporotic rats via activation of SIRT1 signaling pathway. Chem Biol Interact. 2024;388:110827.","journal-title":"Chem Biol Interact"},{"key":"6319_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11010-018-3477-7","volume":"455","author":"S Yan","year":"2019","unstructured":"Yan S, Miao L, Lu Y, Wang L. Sirtuin 1 inhibits TNF-\u03b1-mediated osteoclastogenesis of bone marrow-derived macrophages through both ROS generation and TRPV1 activation. Mol Cell Biochem. 2019;455:135\u201345.","journal-title":"Mol Cell Biochem"},{"key":"6319_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.mce.2018.02.015","volume":"474","author":"B Qu","year":"2018","unstructured":"Qu B, Gong K, Yang H, Li Y, Jiang T, Zeng Z, Cao Z, Pan X. SIRT1 suppresses high glucose and palmitate-induced osteoclast differentiation via deacetylating p66Shc. Mol Cell Endocrinol. 2018;474:97\u2013104.","journal-title":"Mol Cell Endocrinol"},{"key":"6319_CR48","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.3390\/cancers13174277","volume":"13","author":"SH Mehdi","year":"2021","unstructured":"Mehdi SH, Morris CA, Lee JA, Yoon D. An improved animal model of multiple myeloma bone disease. Cancers. 2021;13:4277.","journal-title":"Cancers"},{"key":"6319_CR49","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","volume":"32","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004;32:290\u20132.","journal-title":"Blood Cells Mol Dis"},{"key":"6319_CR50","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos E, Zamagni E, Lentzsch S, Drake MT, Garc\u00eda-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22:e119\u201330.","journal-title":"Lancet Oncol"},{"key":"6319_CR51","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","volume":"110","author":"E Terpos","year":"2007","unstructured":"Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood. 2007;110:1098\u2013104.","journal-title":"Blood"},{"key":"6319_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ajh.21310","volume":"84","author":"A Pennisi","year":"2009","unstructured":"Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 2009;84:6\u201314.","journal-title":"Am J Hematol"},{"key":"6319_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.seminhematol.2012.04.011","volume":"49","author":"YW Qiang","year":"2012","unstructured":"Qiang YW, Heuck CJ, Shaughnessy JD Jr, Barlogie B, Epstein J. Proteasome inhibitors and bone disease. Semin Hematol. 2012;49:243\u20138.","journal-title":"Semin Hematol"},{"key":"6319_CR54","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jbmr.4507","volume":"37","author":"Y Cui","year":"2022","unstructured":"Cui Y, Wang F, Zhang D, Huang J, Yang Y, Xu J, Gao Y, Ding H, Qu Y, Zhang W, et al. Estrogen-responsive gene MAST4 regulates myeloma bone disease. J Bone Miner Res. 2022;37:711\u201323.","journal-title":"J Bone Miner Res"},{"key":"6319_CR55","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/blood-2011-10-384784","volume":"120","author":"DJ Dairaghi","year":"2012","unstructured":"Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012;120:1449\u201357.","journal-title":"Blood"},{"key":"6319_CR56","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood-2012-06-434019","volume":"120","author":"M Sebag","year":"2012","unstructured":"Sebag M. CCR1 blockade and myeloma bone disease. Blood. 2012;120:1351\u20132.","journal-title":"Blood"},{"key":"6319_CR57","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","volume":"110","author":"S Vallet","year":"2007","unstructured":"Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood. 2007;110:3744\u201352.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1186\/s12967-025-07335-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06319-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:02:55Z","timestamp":1771056175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-06319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6319"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06319-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12967-025-07335-z","URL":"https:\/\/doi.org\/10.1186\/s12967-025-07335-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Ethical approval was obtained from the the Ethics Committee of Tianjin Medical University with the approval number IRB2020-KY-109.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication was obtained from all participants, or their legal guardians, in cases where the study involved minors or patients unable to provide consent. Any potentially identifying images have been removed or anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"338"}}